

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

KIEFER et al.

Serial No.: 09/633,200

Filed: August 7, 2000

Atty. File No.: 4588-1-1-DIV4

"METHODS AND COMPOSITIONS For:

FOR DETECTING CDN APOPTOSIS-

MODULATING PROTEINS"

(as amended)

Assistant Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1642

Examiner: Hunt, J.

SUBMISSION OF REFERENCES

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL ADDRESSED TO

Dear Sir:

Pursuant to the Examiner's request in the Office Action dated February 13, 2002 and the Office Action dated August 26, 2002, enclosed are copies of the references cited on Applicants' 1449 form for the above-identified application, which was filed March 16, 2001. Pursuant to 37 CFR 1.98(d), copies of the references were not submitted on March 16, 2001, since the copies should have been of record in the parent application. However, since the Patent Office was unable to locate the references, copies are now provided for the Examiner's convenience and consideration.

Applicants respectfully request that the Examiner consider the enclosed references and initial and date Applicants' 1449 form. Applicants note that the only reference for which a copy is not enclosed is item 55 (Meyn, Cancer Genet., 53:(Abstract No. 1529), 1993). Applicants were unable to locate or obtain a copy of the reference at this time.

Since the original 1449 was timely and properly filed, no fees are believed to be due in connection with this submission, but if fees are due, please debit Deposit Account No. 19-1970.

Respectfully submitted,

SHERIDAN ROSS P.C.

Angela/K. Dallas

Registration No. 42,460

1560 Broadway, Suite 1200 Denver, CO 80202-5141

(303) 863-9700

Date: <u>Movember 21, 2002</u>



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
APPLICANT KIEFER et al.	
FILING DATE August 7, 2000	GROUP ART

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
,	-						

FOREIGN PATENT DOCUMENTS

	TT					SUB	TRANSL	ATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES	NO
*	1	WO 93/04169	3/4/93	PCT				
*	2	WO 94/00572	1/6/94	PCT				
*	3	WO 95/00160	1/5/95	PCT			E	
*	4	WO 95/00642	1/5/95	PCT			740	
*	5	WO 95/05738	3/2/95	PCT			EN	10/
*	6	WO 95/05750	3/2/95	PCT			<u> </u>	100
*	7	WO 95/15084	6/8/95	PCT			16	<i>p I</i>
*	8	WO 96/05232	2/22/96	PCT (Abstract)			1600/2900	
	9	WO 96/33416	10/24/96	PCT		<u> </u>	<u> </u>	
*	10	WO 96/35951	11/14/96	PCT (Abstract)			<u> </u>	

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

*	11	Ameisen et al., Immunol. Today, 12:102-105 (1991)
*	12	Barr, Transgenesis, (1992) Murray, J.A.H., ed., Wiley & Sons, New York, pp. 55-79
*	13	Boise et al., Cell, 74:597-608 (1993)
	14	Bowie et al., Science, 247:1306-1310 (1990)
	15	Brown, "News Media, Researchers 'Oversold' Gene Therapy, Advisory Panel Says," The Washington Post (1995)
	16	Buckel, Trends Pharm. Sci., 17:450-456 (1996)
	17	Callard et al., The Cytokine FactBook, Academic Press, London, p. 31 (1994)
	18	Cazals-Hatem et al., Biochimica et Biophysica Acta, 1132:109-113 (1992)

ΕY	Δľ	M	N	F	R

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MI 2 5 TOR OF SUPERIOR STATE O

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200	
APPLICANT		

FILING DATE August 7, 2000 GROUP ART

*	19	Chen-Levy et al., <i>Mol. Cell. Biol.</i> , 9 :701-710 (1989)
*	20	Cherif et al., <i>Hum. Genet.</i> , 93 :1-6 (1994)
*	21	Chittenden et al., <i>Nature</i> , 347 :733-736 (1995)
*	22	Chittenden et al., <i>EMBO J.</i> , 14 :5589-5596 (1995)
*	23	Cleary et al., <i>Cell</i> , 47 :19-28 (1986)
	24	Coghlan, Focus, 148:14-15 (1995)
*	25	Cohen et al., Ann. Rev. Immunol., 10:267-293 (1992)
	26	Dorin et al., <i>Gene Ther.</i> , 3 :797-801 (1996)
*	27	Duke et al., <i>Lymphokine Res.</i> , 5 :289-299 (1986)
	28	Dzau et al., <i>Proc. Natl. Acad. Sci. USA</i> , 93 :11421-11425 (1996)
*	29	Edgington et al., <i>Biotechnol.</i> , 11 :787-792 (1993)
*	30	Farrow et al., <i>Nature</i> , 374 :731-733 (1995)
*	31	Feinberg et al., Anal. Biochem., 137:266-267 (1984)
*	32	Foroud et al., <i>Am. J. Hum. Genet.</i> , 49 :1263-1279 (1991)
*	33	Gerschenson et al., FASEB J., 6:2450-2455 (1992)
	34	Grossman et al., Nat. Genet., 6:323-324 (1994)
*	35	Henderson et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:8479-8483 (1993)
*	36	Hickish et al., Cancer Research, 54 :2808-2811 (1994)
*	37	Hockenbery et al., <i>Nature</i> , 348 :334-336 (1990) Hockenberry et al., <i>Cell</i> , 75 :241-251 (1993) Jacobson et al., <i>Nature</i> , 361 :365-369 (1993) Kanter et al., <i>Biochem. Biophys. Res. Commun.</i> , 118 :392-399 (1984) Kapp et al., <i>Am. J. Hum. Genet.</i> , 51 :45-54 (1992) Keating et al., <i>Bone Marrow Purging and Processing</i> , 333 :491-498 (1990)
*	38	Hockenberry et al., Cell, 75:241-251 (1993)
*	39	Jacobson et al., <i>Nature</i> , 361 :365-369 (1993)
*	40	Kanter et al., Biochem. Biophys. Res. Commun., 118:392-399 (1984)
*	41	Kapp et al., Am. J. Hum. Genet., 51:45-54 (1992)
	42	Keating et al., Bone Marrow Purging and Processing, 333:491-498 (1990)
*	43	Kennedy, Cancer Res., 54:1999s-2005s (1994)
*	44	Khati et al., Neurology, 43:1131-1137 (1993)
*	45	Kiefer et al., Biochem. Biophys. Res. Commun., 176:219-225 (1991)
*	46	Kiefer et al., Nature, 374:736-739 (1995)
*	47	Klein, J. Clin. Apheresis, 9:139-141 (1994)
*	48	Kruman et al., J. Cell. Physiol., 148:267-273 (1991)
*	49	Lam et al., Proc. Natl. Acad. Sci. USA, 91:6569-6573 (1994)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORW PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200
APPLICANT KIEFER et al.	
FILING DATE	GROUP ART

August 7, 2000

*	50	Lehrach et al., <i>Biochem.</i> , 16 :4743-4751 (1977)
*	51	Lewin, Science, 237:1570 (1987)
	52	Marshall, Science, 269:1050-1055 (1995)
*	53	McDonnell et al., Nature, 349:254-256 (1991)
*	54	McKearn et al., Proc. Natl. Acad. Sci. USA, 82:7414-7418 (1985)
*	55	Meyn, Cancer Genet., 53:(Abstract no. 1529) (1993)
*	56	Monaghan et al., <i>J. Histochem. Cytochem.</i> , 40 :1819-1825 (1992)
	57	Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, PP. 491-495 (1994)
	58	Norrby et al., <i>APMIS</i> , 105 :417-437 (1997)
*	59	Nuñez et al., <i>J. Immunol.</i> , 144 :3602-3610 (1990)
*	60	Oltvai et al., <i>Cell</i> , 74 :609-619 (1993)
	61	Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (1995)
*	62	Orr et al., Nature Genetics, 4:221-226 (1993)
*	63	Pearson et al., Virology, 160:151-161 (1987)
*	64	Pinkel et al., <i>Proc. Natl. Acad. Sci. USA</i> , 85 :9138-9142 (1988)
*	65	Reeck, Cell, 50:667 (1987)
*	66	Reed et al., Cancer Res., 50:6565-6570 (1990)
*	67	Sanger et al., Proc. Natl. Acad. Sci. USA, 74:5463-5467 (1977)
*	68	Sanger et al., <i>Proc. Natl. Acad. Sci. USA</i> , 74 :5463-5467 (1977) Sentman et al., <i>Cell</i> , 67 :879-888 (1991) Sheppard et al., <i>J. AIDS</i> , 5 :143-147 (1992) Strasser et al., <i>Cell</i> , 67 :889-899 (1991) Tarodi et al., <i>Virology</i> , 201 :404-407 (1994) Thomas, <i>Proc. Natl. Acad. Sci. USA</i> , 77 :5201-5205 (1980) Tomei et al., <i>Biochem. Biophys. Res. Commun.</i> , 155 :324-331 (1988)
*	69	Sheppard et al., J. AIDS, 5:143-147 (1992)
*	70	Strasser et al., Cell, 67:889-899 (1991)
*	71	Tarodi et al., Virology, 201:404-407 (1994)
*	72	Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)
*	73	Tomei et al., Biochem. Biophys. Res. Commun., 155:324-331 (1988)
*	74	Tsujimoto et al., <i>Science</i> , 226 :1097-1099 (1984)
*	75	Veis et al., Cell, 75:229-240 (1993)
*	76	Viegas-Péquignot, In Situ Hybridization. A Practical Approach, D.G. Wilkinson, ed., IRL Press, Oxford, pp. 137-159
*	77	Williams et al., Cell, 74:777-779 (1993)
*	78	Wyllie, <i>Nature</i> , 284 :555-556 (1980)
*	79	Yonehara et al., <i>J. Exp. Med.</i> , 169 :1747-1756 (1989)
*	80	Zapf et al., J. Biol. Chem., 265:14892-14898 (1990)

EX	AΜ	INI	ĒF
----	----	-----	----

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4588-1-1-DIV4	SERIAL NO. 09/633,200	
APPLICANT KIEFER et al.		
FILING DATE	GROUP ART	

*	01	7hu et al. Crimes 204 000 044 (400)
	0	Zhu et al., Science, 261 :209-211 (1993)

August 7, 2000

BOOK THE STATE OF THE STATE OF

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.